CRASH-3

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH – 3): a randomised, placebo-controlled trial The CRASH-3 trial collaborators. The Lancet, 2019; doi.org/10.1016/S1040-6736(19)32233-0 Clinical Question In patients with traumatic brain injury (TBI), does the administration of tranexamic acid (TXA) under 3 hours from injury, compared with placebo, reduce […]

Continue reading »